TriangleQuality-of-Life Assessment (NCT04623931)
Quality-of-Life Assessment trial for Anaplastic Astrocytoma, IDH-Wildtype (NCT04623931). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with IDH-wildtype gliomas historically called grade II or III, including tumors now classified as molecular glioblastoma. Previous chemotherapy or radiation for a brain tumor is excluded.
The idea: temozolomide changes DNA to disrupt copying; radiation uses high-energy X-rays against tumors. Researchers test intensified radiation with daily oral temozolomide for six weeks. Four weeks after radiation, temozolomide continues for up to twelve months. They track progression, survival, cognition, and symptoms.
This phase 2 study plans 40 patients. Debra Yeboa leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.